Bo Zheng, Jian Yang, Yan Li, Gangfeng Gu, Xiaojing Luo, Xiaolan Luo, Zhao Chen, Ke Huang, Yang Fan, Maoxia Li, Jian Wang
Department of Neurology, Ya'an People's Hospital, China.
Department of Laboratory, Ya'an People's Hospital, China.
Oxid Med Cell Longev. 2022 Aug 18;2022:3511385. doi: 10.1155/2022/3511385. eCollection 2022.
Central post-stroke pain (CPSP) is a common condition. Several pharmacotherapies have been applied in practice. However, the comparative effectiveness among these pharmacotherapies is unknown.
The aim of this study is to study the comparative effectiveness among differential pharmacotherapies for CPSP through a network meta-analysis.
We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science from inception to 30 March 2022, without any language restriction. Two reviewers independently screened the retrieved articles, extracted data, and evaluated the risk of bias (RoB). The outcome of interest of the study was the change in the scores of pain intensity scales. We estimated standard mean differences (SMDs) between treatments and calculated corresponding 95% CIs.
Thirteen randomized controlled trials (529 participants) were included after a screen of 1774 articles. Compared with placebo, pamidronate (SMD -2.43, 95% CI -3.54 to -1.31; - score = 0.93), prednisone (SMD -2.38, 95% CI -3.09 to -1.67; - score = 0.92), levetiracetam (SMD -2.11, 95% CI -2.97 to -1.26; - score = 0.87), lamotrigine (SMD -1.39, 95% CI -2.21 to -0.58; - score = 0.73), etanercept (SMD -0.92, 95% CI -1.8 to -0.03; - score = 0.59), and pregabalin (SMD -0.46, 95% CI -0.71 to -0.22; - score = 0.41) had significantly better treatment effect. Pamidronate, prednisone, and levetiracetam ranked as the first three most effective treatments. In subgroup analyses, prednisone, levetiracetam, lamotrigine, and pregabalin were more effective than placebo as oral pharmacotherapies, while etanercept was more effective than placebo as injectable pharmacotherapy.
Our study confirmed that pamidronate, prednisone, and guideline-recommended anticonvulsants were effective for reducing pain intensity for CPSP. Pamidronate and prednisone showed better effect than other pharmacotherapies, which warrants further investigation.
中风后中枢性疼痛(CPSP)是一种常见病症。实践中已应用多种药物疗法。然而,这些药物疗法之间的相对疗效尚不清楚。
本研究旨在通过网络Meta分析研究不同药物疗法治疗CPSP的相对疗效。
我们检索了MEDLINE、EMBASE、Cochrane对照试验中心注册库(CENTRAL)和Web of Science,检索时间从建库至2022年3月30日,无语言限制。两名研究者独立筛选检索到的文章,提取数据并评估偏倚风险(RoB)。本研究的主要结局是疼痛强度量表评分的变化。我们估计了各治疗组之间的标准均数差(SMD)并计算了相应的95%置信区间(CI)。
在筛选的1774篇文章中,纳入了13项随机对照试验(529名参与者)。与安慰剂相比,帕米膦酸(SMD -2.43,95%CI -3.54至-1.31;I²评分=0.93)、泼尼松(SMD -2.38,95%CI -3.09至-1.67;I²评分=0.92)、左乙拉西坦(SMD -2.11,95%CI -2.97至-1.26;I²评分=0.87)、拉莫三嗪(SMD -1.39,95%CI -2.21至-0.58;I²评分=0.73)、依那西普(SMD -0.92,95%CI -1.8至-0.03;I²评分=0.59)和普瑞巴林(SMD -0.46,95%CI -0.71至-0.22;I²评分=0.41)的治疗效果显著更好。帕米膦酸、泼尼松和左乙拉西坦位列最有效的前三种治疗方法。在亚组分析中,作为口服药物疗法,泼尼松、左乙拉西坦、拉莫三嗪和普瑞巴林比安慰剂更有效,而作为注射药物疗法,依那西普比安慰剂更有效。
我们的研究证实,帕米膦酸、泼尼松和指南推荐的抗惊厥药物对降低CPSP的疼痛强度有效。帕米膦酸和泼尼松比其他药物疗法效果更好,值得进一步研究。